About Zinc finger protein 233
Zinc finger protein 233 (ZNF233) is a protein
from Homo sapiens identified by UniProt accession
A6NK53, 670 residues long.
MolForge cross-references it against 0 known binders and
6 disease associations.
Target properties
| Protein name | Zinc finger protein 233 |
| UniProt accession | A6NK53 |
| Gene | ZNF233 |
| Organism | Homo sapiens |
| Length | 670 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (6)
Diseases linked to this target (Open Targets).
- C-reactive protein measurement · score 0.14
- hepatocellular carcinoma · score 0.02
- neoplasm · score 0.00
- cancer · score 0.00
- uterine leiomyosarcoma · score 0.00
- juvenile idiopathic arthritis · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-A6NK53-F1 | alphafold | PREDICTED | 52.69 | — |
Amino-acid sequence (670 residues)
MTKFQEMVTF KDVAVVFTRE ELGLLDLAQR KLYQDVMLEN FRNLLSVGYQ PFKLDVILQL GKEDKLRMME TEIQGDGCSG HKNQNEIDTL QEVRLRFLSY EDLICWQIWE QFTSKLTSNQ DLIINLQGKR SKLLKQGDSP CQVWTGESSQ VSEDENYVIK LQGESSNSIK NQELPLRTTW DFWRKMYLRE PQNYQSRCQQ IDVKNKLCKC DHCVRQRIAH QHDDHGVHKR EKAFSHNNCG KDCVKESSQH SIIQSGEQTS DENGKGLSVG SNLELHQQLH LRDKPHVNVE YGKGIGYSSG LPRHQCFHIG EKCYRNGDSG EGFSQGSHLQ PHQRVSTGEN LYRCQVYARS SNQNSCLPSH ELTHPGEKLC TCGRCGKGFH HSLDFDIHCV DSAGERACKC DVYDKGFSQT SQLQAHQRGH SRDKTYKWEV SDRIFNRNSG LHQRVHTGEK PYKCEVCDKG FSKASNLQAH QRIHTGEKPY KCDVCDKNFS RNSHLQAHQR VHTGEKPYKC DTCGKDFSQI SHLQAHQRVH KGEKPYKCET CGKGFSQSSH LQDHQQVHTG ENPYKCDVCG KGFSWSSHLQ AHQRVHTGEK PYKCEECRKG FIWNSYLHVH QRIHTGEKPY KCGMCGKSFS QTSHLQAHQR VHTGEKPYKC FVCGKGFSKS SLSSDSSESP
Explore Zinc finger protein 233 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets